NYSDOH CLEP Laboratory Developed Test Compliance Consulting — Integral Healthcare Solutions

Last updated: April 2026

Last updated: April 2026

New York State is the only U.S. jurisdiction that mandates formal pre-market review and approval of Laboratory Developed Tests (LDTs). Any laboratory — regardless of physical location — that tests specimens from New York residents must hold a valid NYSDOH permit with CLEP-approved LDTs. IHS guides laboratories through the full CLEP compliance lifecycle: gap assessment, method validation documentation, application submission, RFI response, on-site survey preparation, and annual permit renewal.

Data scarcity note: NYSDOH does not publish ranked quantitative deficiency statistics. Content on this page is derived from NYSDOH regulatory documents, published academic research, and IHS consulting experience. Where data is limited, we say so explicitly.

Schedule a CLEP Gap Assessment with IHS

What Is NYSDOH CLEP and Why Does New York Regulate LDTs Differently?

The New York State Clinical Laboratory Evaluation Program (CLEP), administered by the NYSDOH Wadsworth Center, has reviewed and approved laboratory developed tests since 1991 — processing over 15,000 LDT applications in its history (NYSDOH Wadsworth Center). CLEP is not a voluntary accreditation program. It is a mandatory state regulatory requirement with permit conditions, annual renewal obligations, and on-site inspection authority.

CLEP goes substantially further than federal CLIA certification. While CLIA governs laboratory operations, personnel, and quality systems, NYSDOH CLEP requires formal pre-market technical review of the test methodology itself — validating that each LDT performs as claimed before laboratories may report results on New York specimens. This includes clinical validity proof (literature or trial data) that exceeds CLIA requirements.

As of 2025, approximately 1,146 laboratory facilities hold NYSDOH CLEP LDT approvals, collectively maintaining approximately 10,977 approved LDTs on the active registry (NYSDOH Approved LDT Registry). Critically: 77% of CLEP LDT submissions originate from outside New York State, with only 23% from in-state laboratories and 0.2% international (Journal of Molecular Diagnostics 2025). The demand for CLEP consulting is national, not local.

Who Must Obtain NYSDOH CLEP Approval?

Any laboratory that performs LDTs on specimens from New York residents must hold a NYSDOH permit with those tests approved through CLEP — regardless of where the laboratory is physically located. This extraterritorial reach is unique among U.S. jurisdictions and is the primary reason that major commercial reference laboratories, academic medical centers, and specialty diagnostic labs across all 50 states must navigate NYSDOH CLEP.

Five categories of organizations most commonly need CLEP consulting:

• Molecular and genomic diagnostic laboratories — NGS panels for oncology, pharmacogenomics, and rare genetic diseases carry the most complex CLEP validation requirements
• Commercial reference laboratories — national operations cannot be locked out of the New York market; CLEP approval is a market access requirement
• Clinical trial sponsors and central labs — companion diagnostics and biomarker assays used in trials enrolling New York subjects require CLEP approval
• Hospital-at-Home and novel delivery model developers — recent CLEP updates include provisions supporting HaH services; organizations developing point-of-care LDTs for non-traditional settings need CLEP guidance
• Academic medical center laboratories — developing novel assays and seeking payer coverage acceleration through CLEP's government-backed validity proxy status

NYSDOH CLEP vs. CLIA vs. CAP: Key Differences

CLIA certification is necessary but not sufficient for testing New York specimens. CLEP is an additional, independent requirement that operates in parallel with federal oversight — not as a substitute for it.

CAP accreditation does not satisfy NYSDOH CLEP requirements. A CAP-accredited laboratory still requires a separate NYSDOH permit and individual CLEP approval for each LDT it performs on New York specimens. These are independent regulatory frameworks with separate application processes, separate fees, and separate inspection authorities.

The 2024 FDA LDT Rule, Its Vacatur, and What It Means for CLEP

The FDA LDT regulatory landscape underwent dramatic shifts in 2024 and 2025 — and the net result elevated CLEP's status from a regional compliance obligation to the undisputed national gold standard for LDT quality validation.

• May 2024: FDA issued a final rule to regulate LDTs as medical devices. Critically, the rule explicitly exempted CLEP-approved tests from premarket review — triggering a surge in CLEP applications as laboratories sought the FDA safe harbor advantage
• March 31, 2025: U.S. District Court for the Eastern District of Texas vacated the FDA's May 2024 LDT rule, holding that FDA lacked statutory authority to regulate LDTs as medical devices. FDA chose not to appeal (FDA)
• September 19, 2025: FDA formally published a final rule reverting regulatory text to pre-May 2024 status. Federal LDT oversight returned to CLIA/CMS. CLEP is now the only rigorous pre-market LDT review framework operating in the United States (FDA)

The practical consequence: with FDA oversight of LDTs vacated and the regulatory landscape uncertain at the federal level, payers, hospital systems, and institutional partners increasingly treat CLEP approval as the proxy for diagnostic validity that FDA premarket review would otherwise have provided. CLEP approval accelerates payer reimbursement from Medicare MACs and commercial insurers. For laboratories developing novel LDTs, CLEP approval is now the primary external validation credential available.

The NYSDOH Tiered Risk Classification System

NYSDOH assigns each submitted LDT to a risk tier that determines the depth of technical review, the timeline for conditional approval, and the requirements for on-site inspection. Understanding risk tier assignment is critical for timeline planning and resource allocation.

• Low Risk: Approximately 34% of all submitted tests receive immediate full approval (Journal of Molecular Diagnostics 2025). Low-risk tests use well-established methodologies with extensive published clinical validity data and present minimal public health risk if results are inaccurate.
• Moderate Risk: Tests receive conditional approval — laboratories may begin billing for services while the state completes its technical review. This is the most operationally advantageous tier for commercial reference laboratories seeking uninterrupted market access.
• High Risk: Tests with novel methodologies, limited clinical validation data, or significant clinical consequence if inaccurate. Full technical review required before any approval is granted. Most NGS oncology panels and companion diagnostics fall here.
• Clinical Trial Category: Tests used exclusively in FDA-regulated clinical trials with separate oversight requirements.
• Exempt: Tests meeting specific criteria for exemption from the full CLEP review process.

Risk tier assignment is made by NYSDOH after reviewing the Risk Attestation Form submitted with the application. IHS helps organizations complete the Risk Attestation Form in ways that accurately represent the test while supporting the most favorable tier assignment the data can support.

The CLEP LDT Approval Process: Documentation and Timeline

Initial CLEP approval typically takes 12 to 14 months from gap assessment to full permit issuance. Existing permitted laboratories adding new LDT categories can expect 6 to 9 months. The 54% RFI rate for initial applications (Journal of Molecular Diagnostics 2025) means that most organizations will face at least one round of NYSDOH technical questions — and the 60-day response window is firm. Missing it causes automatic application inactivation.

Step 0: Laboratory Director CQ (2–4 Months)

The Laboratory Director must hold a New York State Certificate of Qualification (CQ) in the exact testing categories before the facility can submit its application. NYSDOH processes CQ applications independently — this step cannot be accelerated by the facility or its consultant. It must begin immediately upon engagement. Proposed Subpart 58-6 (opened for public comment December 2025) will allow Lab Directors to oversee up to 5 facilities at minimum 8 hours per week on-site per facility under updated rules.

Phase 1: Gap Assessment (Weeks 1–3)

IHS reviews existing SOPs, validation data, QMS documentation, and personnel records against NYSDOH CLEP standards. Risk classification of proposed tests is determined. Personnel CQ requirements are mapped. Every documentation gap is identified and prioritized.

Phase 2: Documentation Build (Months 1–4)

Draft SOPs for all pre-analytic, analytic, and post-analytic processes. Compile method validation data meeting CLEP's clinical validity requirements — which exceed CLIA. Complete the Risk Attestation Form with supporting data. Prepare category-specific checklists (Genetic Testing-Molecular, Oncology, Toxicology, Trace Elements, Microbiology, or General). For NGS panels, this phase requires bioinformatics documentation expertise — variant classification pipelines, reference databases, and analytical sensitivity/specificity data across relevant variant classes.

Phase 3: Preliminary Submission (Month 4–5)

Submit via the eCLEP portal: facility demographics, ownership disclosures, Facility Personnel Form (FPF) through the Health Commerce System (HCS), proficiency testing provider authorization. NYSDOH assigns risk tier within 3 to 6 weeks. IHS anticipates common RFI triggers and pre-addresses them in the submission package to minimize rounds of back-and-forth.

Phase 4: RFI Response (Up to 60 Days from RFI)

54% of applications receive at least one RFI. IHS drafts technically accurate, concise responses to NYSDOH technical questions in both digital and hard copy formats required by CLEP. A missed 60-day RFI deadline automatically inactivates the application — all work to date is lost. IHS manages RFI response timelines as a core project management function.

Phase 5: On-Site Survey

CLEP surveyors verify QMS implementation on bench, assess personnel competency, and observe actual testing processes. Out-of-state laboratories pay all NYSDOH surveyor travel expenses — airfare, lodging, and per diem — in addition to the standard inspection fee. IHS prepares laboratory staff for surveyor interactions, competency demonstrations, and the documentation audit that accompanies every on-site inspection.

Phase 6: Permit Issuance

A comprehensive permit is issued only after all survey deficiencies are corrected, all LDT technical approvals are granted, and all invoices are cleared. The permit runs on an annual cycle (July 1 – June 30). Annual reapplication opens March 28 and is due April 28.

Internal Staffing Requirements

• Laboratory Director with NY CQ — 1.0 FTE; must document sufficient on-site hours under proposed Subpart 58-6
• QMS Manager — 0.5 to 1.0 FTE for documentation and CAPA management
• Bioinformatics staff — required for NGS validation data packages
• Laboratory personnel — participation in competency testing and proficiency testing programs

NYSDOH CLEP Fees and Consulting Costs

NYSDOH CLEP fees are among the most transparent elements of the program. The regulatory cost of CLEP is low — the high cost is the consulting and internal expertise required to meet NYSDOH's rigorous technical standards.

NYSDOH Direct Fees

• Initial application fee: $100 (non-refundable) (NYSDOH CLEP Program Guide 2025)
• Inspection and reference fee: $1,000 at initial application
• Total initial baseline: $1,100
• Annual maintenance fee: Calculated using the GAR (Gross Annual Revenue) formula — NYSDOH total operating expenses multiplied by individual lab GAR divided by total combined GAR of all permitted labs. Out-of-state labs: GAR = New York specimen revenue only. In-state labs: GAR = global revenue.
• Out-of-state lab travel fees: All NYSDOH surveyor travel expenses (airfare, lodging, per diem) — a significant additional cost for non-New York laboratories

Consulting Fees

Data scarcity: No public pricing exists for NYSDOH CLEP consulting. IHS provides custom engagement quotes based on organizational scope.

• Comprehensive CLEP engagement (initial permit): Comparable to FDA regulatory affairs engagements — $40,000–$50,000+ baseline for complex molecular or genomic programs
• NGS panel validation packages: Scope and cost higher due to bioinformatics documentation complexity
• Adding new LDT categories to existing permit: Substantially lower than initial permit — contact IHS for scope assessment
• Annual renewal support: Retainer-based; scoped based on number of LDTs and anticipated RFI volume

Common CLEP Inspection Deficiencies

Note: NYSDOH does not publish ranked quantitative deficiency statistics. The following is derived from 2024–2025 CLEP regulatory updates and IHS consulting experience with laboratory compliance programs.

Quality Management System Deviations

Failure to conduct scheduled annual internal audits across all testing phases. Failure to document formal Corrective and Preventive Action (CAPA) when quality indicators are missed. NYSDOH's QMS requirements under Subpart 58-1 are more operationally rigorous than CLIA — documented CAPA records are mandatory for any quality event, not optional.

Director and Supervisor Involvement Documentation

The Lab Director must spend adequate, documented time overseeing operations. Under proposed Subpart 58-6, a director overseeing multiple facilities must maintain minimum 8 hours per week on-site per facility — with documentation. NYSDOH surveyors pull director on-site attendance records. Organizations where the Lab Director is primarily off-site face citation risk.

Proficiency Testing Failures

Unsuccessful external PT is immediately visible to NYSDOH. Failures result in a Laboratory Evaluation Report with 2-week warning notifications or — for high-risk tests — immediate cease-testing orders. IHS implements PT program monitoring and failure response protocols that minimize the window between PT failure and corrective documentation.

Releasing Results Before Investigating Non-Conforming Events

Reporting patient test results before a non-conforming event (failed calibration, out-of-range control) has been fully investigated, corrected, and documented. This is a bright-line CLEP violation. IHS builds reporting hold protocols into QMS documentation to prevent this from occurring in routine operations.

Record Retention Violations

NYSDOH requires HR, training, and competency records for employment duration plus 6 years; safety training records for 3 years. Record retention gaps are "low-hanging fruit" for surveyors — easy to cite, easy to prevent. IHS audits retention schedules in every engagement.

Unapproved Method Modifications

Altering specimen type, changing a reagent supplier, or shifting a test's intended use claim without submitting a formal modification validation package to Wadsworth Center. Any change to an approved LDT that affects performance characteristics requires NYSDOH notification and re-approval. IHS builds change control processes that trigger the appropriate CLEP notification workflows automatically.

Why Choose IHS for NYSDOH CLEP Compliance Consulting

The NYSDOH CLEP consulting market is nearly empty. A single partially paywalled academic paper and one small consulting firm represent almost the entire competitive landscape for practical CLEP guidance. IHS can provide depth of regulatory analysis that no public source currently offers.

• First-mover advantage: IHS can build comprehensive CLEP content at a moment when almost no consulting firm has established authority in this niche. Organizations searching for CLEP guidance will find IHS.
• FDA regulatory context expertise: The 2024 rule issuance, safe harbor, vacatur, and September 2025 reversion created a complex narrative that most laboratory compliance professionals have not tracked in detail. IHS understands the full regulatory timeline and its practical implications for CLEP's current status as the national LDT quality standard.
• Out-of-state lab specialization: 77% of CLEP applicants are from outside New York. IHS specifically addresses the unique compliance burden these organizations face: GAR calculation on New York-only revenue, surveyor travel cost planning, and remote QMS documentation management.
• NGS and genomics validation expertise: The most complex CLEP submissions involve NGS oncology panels, pharmacogenomic tests, and rare disease assays. IHS provides bioinformatics-informed documentation guidance that addresses NYSDOH's analytical and clinical validity requirements for these test categories.
• RFI management as a core service: With 54% of applications receiving RFIs and a hard 60-day response deadline, RFI management is not peripheral to CLEP consulting — it is central. IHS treats RFI anticipation and response as a primary deliverable in every engagement.
• Principal-led engagement: Thomas G. Goddard, JD, PhD, leads every IHS engagement. You work directly with the firm's principal, not a junior consultant.

Frequently Asked Questions

See our complete NYSDOH CLEP LDT Compliance FAQ for detailed answers to 12+ questions.

Does my laboratory need NYSDOH CLEP approval if it is located outside New York?

Yes. Any laboratory that tests specimens from New York residents must hold a valid NYSDOH permit with CLEP-approved LDTs — regardless of where the laboratory is physically located. 77% of CLEP submissions come from outside New York (Journal of Molecular Diagnostics 2025). CLIA certification does not satisfy this requirement; CLEP is an additional, independent regulatory obligation.

Does CAP accreditation satisfy NYSDOH CLEP requirements?

No. CAP accreditation and NYSDOH CLEP are independent regulatory frameworks. A CAP-accredited laboratory still requires a separate NYSDOH permit and individual CLEP approval for each LDT performed on New York specimens. CAP accreditation may be presented as evidence of quality systems maturity during the CLEP application process, but it does not substitute for or satisfy CLEP's pre-market LDT review requirement.

What are the consequences of testing New York specimens without CLEP approval?

Testing New York specimens without a valid NYSDOH permit and CLEP-approved LDTs is unlawful under New York Public Health Law. Consequences can include cease-testing orders, civil penalties, permit denial or revocation, and exclusion from New York Medicaid reimbursement. Laboratories that discover they have been testing New York specimens without approval should contact IHS immediately — the remediation pathway is well-defined, but it requires prompt action.

How does the tiered risk classification affect the approval timeline?

Low-risk LDTs can receive immediate full approval — approximately 34% of submissions. Moderate-risk tests receive conditional approval allowing billing to continue while review proceeds. High-risk tests require full technical review before any approval, extending the timeline and requiring the most comprehensive validation documentation. IHS helps organizations understand their test's likely risk tier before submission and prepares documentation accordingly.

Ready to Pursue NYSDOH CLEP Approval?

Schedule a no-obligation gap assessment with Thomas G. Goddard, JD, PhD. IHS will assess your laboratory's current compliance posture against NYSDOH CLEP requirements and give you a clear roadmap to permit issuance — including Lab Director CQ planning, documentation requirements, and RFI risk mitigation strategy.

Schedule Your CLEP Gap Assessment